»
Progress in Medicinal Chemistry
 
 

Progress in Medicinal Chemistry, 1st Edition

 
Progress in Medicinal Chemistry, 1st Edition,F.D. King,G. Lawton,ISBN9780444528087
 
 
Up to
25%
off
 

Progress in Medicinal Chemistry

King   &   Lawton   

Elsevier Science

9780444528087

9780080471310

232

280 X 210

A highly valuable reference for medicinal chemists, biologists, doctors, and pharmacists

Print Book + eBook

USD 252.00
USD 420.00

Buy both together and save 40%

Print Book

Hardcover

In Stock

Estimated Delivery Time
USD 161.25
USD 215.00

eBook
eBook Overview

VST format:

DRM Free included formats: PDF

USD 153.75
USD 205.00
Add to Cart
 
 

Key Features

*Presents the latest research in the field of drug discovery
*Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry
*Available as an online resource via ScienceDirect

Description

The success of any drug discovery project relies upon the quality of the lead that initiates the lead optimization process. What defines a ‘quality lead’, where these ‘quality leads’ come from and how one discovers them has been the subject of intense debate within the pharmaceutical industry, relies upon defining those properties that historically have led to successful drug discovery. This volume addresses these questions and specifically discusses diabetes, obesity and tuberculosis.

Readership

Chemists, biologists, doctors, pharmacists and anyone interested in the contemporary controversy about drugs, drug firms, and the community

F.D. King

Affiliations and Expertise

GlaxoSmithKline, Harlow, Essex, UK

View additional works by F.D. King

G. Lawton

Dr Geoff Lawton has extensive experience in new medicine discovery across many therapeutic areas in both large and small companies and is a co-inventor of a marketed drug (Cilazapril). He is a former Director of Chemistry at Roche UK, and Vice-president Chemistry and Preclinical Sciences within Roche Bioscience, Palo Alto, USA. He was for five years the research member of a global therapy area strategy planning team for inflammatory diseases, aligning research with the clinical development and marketing parts of the business. From 2003 to 2007 he was founding Research Director with Lectus Therapeutics building from start-up a drug discovery organisation; generating the team, facilities and project portfolio targeting the next generation of ion channel modulating medicines. Since 2001 Geoff has provided scientific and strategic evaluation and advice on drug discovery as an independent consultant for a number small and medium sized biotech companies, CROs, VCs, academic groups and medical research charities. Geoff serves on the Board of Antabio, a French biotech company developing tomorrow’s antibacterial drugs. He is a founder of INMedD, a new medicines discovery social enterprise.

Affiliations and Expertise

St. Ippolyts, Herts, UK

View additional works by G. Lawton

Progress in Medicinal Chemistry, 1st Edition

Preface
List of Contributors
Hit and Lead Identification: Efficient practices for drug discovery
DPPIV Inhibition: Promising Therapy for the Treatment of Type 2 Diabetes
Recent Progress Towards Nonpeptide Ligands for the Melanocortin-4 Receptor
Tuberculosis chemotherapy: recent developments and future perspectives
Subject Index
Author Index (Volumes 1-45)
Subject Index (Volumes 1-45)
 
 
Save up to 25% on all Books
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy
FAQ

Contact Us